---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000005"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:21.595503+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M

## Summary
- ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.
- 2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.
- Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.
- KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.
- ~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch.

## SEC filing metadata
- accession: 0001730430-26-000005
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/0001730430-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/knsa-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000005
- JSON: https://secwatch.observer/filing/0001730430-26-000005.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.